Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

NasdaqGS:HLIT
NasdaqGS:HLITCommunications

A Look At Harmonic (HLIT) Valuation After TDF Adopts Its AI‑Driven Broadcast Technology

Harmonic (HLIT) is back in focus after TDF, a major French broadcast infrastructure operator, upgraded its nationwide terrestrial network using Harmonic’s XOS and ProStream X platforms, spotlighting the company’s media processing capabilities. See our latest analysis for Harmonic. Despite the TDF and KBRO wins and new sports streaming features, Harmonic’s recent momentum has been mixed, with a 30 day share price return of a 7.35% decline contrasting with a 1 year total shareholder return of...
NYSE:AORT
NYSE:AORTMedical Equipment

Should Artivion’s Q4 Revenue Miss Amid Strong Product Growth Require Action From AORT Investors?

Artivion’s recent Q4 results showed revenue rising 19.2% year on year, driven by strong growth in stent grafts, On-X products, and preservation services, but coming in just 0.8% below analyst expectations. Despite delivering solid full-year 2025 adjusted revenue and EBITDA growth, Artivion’s relatively weaker performance versus peer estimates raises questions about how much near-term momentum investors should expect. Next, we’ll examine how this slight quarterly revenue miss, despite strong...
NasdaqGS:ROIV
NasdaqGS:ROIVBiotechs

Roivant Sciences (ROIV) Is Up 6.8% After Mixed Autoimmune Trial Updates - Has The Bull Case Changed?

In early April 2026, Roivant Sciences reported mixed clinical updates, including Priovant’s launch of a Phase 2b/3 brepocitinib trial in lichen planopilaris and Immunovant’s Phase 3 batoclimab thyroid eye disease studies not meeting their primary endpoint. The brepocitinib program now spans four late-stage indications and has Priority Review for dermatomyositis, underscoring Roivant’s emphasis on high-need autoimmune conditions despite setbacks for batoclimab. We’ll now examine how the...
NYSE:TEVA
NYSE:TEVAPharmaceuticals

How Investors Are Reacting To Teva (TEVA) Advancing Its Biosimilar Pipeline With New FDA and EMA Milestones

In late March 2026, Teva Pharmaceutical Industries reported three biosimilar milestones, including US FDA approval of PONLIMSI (denosumab-adet) as a biosimilar to Prolia for all its osteoporosis-related indications, alongside FDA and EMA acceptance of filings for a proposed Xolair (omalizumab) biosimilar across its full label. These advances highlight Teva’s effort to broaden its higher-value biopharmaceutical portfolio, using biosimilars to complement its generics base and support its Pivot...
XTRA:O5G
XTRA:O5GReal Estate

CPI Property Group (XTRA:O5G) Valuation Check After Return To Profit And Higher Occupancy

CPI Property Group (XTRA:O5G) just reported full year 2025 results, returning to a net profit of €185.6 million while revenue and sales softened, and occupancy reached 93% with €1.1b of property disposals completed. See our latest analysis for CPI Property Group. The latest earnings release and balance sheet moves appear to have steadied sentiment, with a 1.38% 1 day share price return. However, a 5.77% 90 day share price decline and a 9.82% 1 year total shareholder return decline suggest...
NYSE:WU
NYSE:WUDiversified Financial

Assessing Western Union (WU) Valuation After Jim Cramer Comments And Recent Share Price Move

Recent comments from television host Jim Cramer, who questioned Western Union (WU) as a growth idea despite its dividend appeal, have put the stock back in focus after a roughly 6.5% move higher. See our latest analysis for Western Union. The recent 6.5% share price move and 1 day share price return of 2.96% come against a weaker backdrop, with a 30 day share price return of 10.21% and a 1 year total shareholder return of 4.4% and 5 year total shareholder return of 49.31%. This suggests...
NasdaqGM:MIRM
NasdaqGM:MIRMBiotechs

Assessing Mirum Pharmaceuticals (MIRM) Valuation After Record Revenues First GAAP Profitability And Key Trial Milestones

Mirum Pharmaceuticals (MIRM) has drawn fresh attention after reporting record quarterly net product revenue, raising full year revenue guidance, achieving its first GAAP profitability, and completing enrollment in several key clinical trials. See our latest analysis for Mirum Pharmaceuticals. The recent clinical and regulatory milestones appear to have fed into strong momentum, with a 90 day share price return of 20.62% and a 1 year total shareholder return of 124.05%. The current share price...
NYSE:FCN
NYSE:FCNProfessional Services

Is FTI Consulting’s (FCN) New AI Governance Leader a Signal on Its Long-Term Tech Strategy?

In March 2026, FTI Consulting, Inc. appointed Kelly Henney as Senior Managing Director and Australia Leader of its Information Governance, Privacy & Security practice within the Technology segment, based in Sydney. Her background in artificial intelligence governance, data privacy, and digital risk, combined with legal and banking experience, enhances FTI’s ability to advise clients on complex regulatory and compliance challenges. Next, we’ll examine how Henney’s artificial intelligence...
NYSE:FLNG
NYSE:FLNGOil and Gas

How Investors May Respond To FLEX LNG (FLNG) Extending Flex Aurora Charter And Lifting Contract Backlog

In March 2026, Flex LNG Ltd. announced a new time charter for the Flex Aurora with a Supermajor, securing a firm two-year term plus optional extensions that could keep the vessel employed through 2034 and lift the company’s total contract backlog to a minimum of 55 years, or up to 82 years if all options are used. This incremental charter backlog adds further revenue visibility at a time when the company has flagged potential revisions to its full-year 2026 guidance amid volatile LNG...
NasdaqGS:CORZ
NasdaqGS:CORZSoftware

Why Core Scientific (CORZ) Is Up 7.7% After Doubling Its Delayed-Draw Credit Facility To $1 Billion

On March 18, 2026, Core Scientific, Inc. entered into an amendment to its Delayed-Draw Bridge Credit Agreement, increasing total term loan commitments by US$500.0 million to US$1.0 billion and drawing the full incremental amount on the closing date. This substantial expansion of borrowing capacity materially alters Core Scientific’s financial flexibility, potentially affecting how it funds high‑performance computing projects and manages its evolving capital structure. We’ll now examine how...
NYSE:PHR
NYSE:PHRHealthcare Services

A Look At Phreesia (PHR) Valuation After Fiscal 2027 Guidance Cut And Analyst Downgrades

Why Phreesia’s latest guidance cut matters for investors Phreesia (PHR) has drawn fresh attention after issuing lower fiscal 2027 revenue guidance, tying the reset to weaker spending from pharmaceutical clients. The announcement triggered a sharp share price drop and several analyst downgrades. See our latest analysis for Phreesia. The lowered fiscal 2027 revenue outlook, combined with mixed fourth quarter results and analyst downgrades, has sharply shifted sentiment. A 7 day share price...
NasdaqCM:NN
NasdaqCM:NNSoftware

Is Growing Optimism Around FCC Action Reframing NextNav's (NN) Spectrum Story or Just Sentiment Noise?

In late March 2026, investors reacted to easing geopolitical tensions and a broader relief rally as confidence improved around NextNav’s prospects for an FCC Notice of Proposed Rulemaking tied to its 5G-based terrestrial GPS backup system. This shift in sentiment highlights how progress toward a clearer regulatory path can become a central driver of interest in NextNav’s spectrum-backed positioning and timing platform. Now we’ll examine how growing optimism around the FCC regulatory...
NYSE:BKV
NYSE:BKVOil and Gas

Assessing BKV (BKV) Valuation After Oil Driven Sector Pullback

Oil driven pullback puts BKV in focus The recent easing of U.S. Iran tensions pushed oil prices lower, dragging energy names with them as traders locked in gains after a strong run and technical gauges flagged oversold conditions across the sector. BKV (BKV) was caught in that macro driven move, with selling pressure tied less to company specific headlines and more to shifting sentiment toward oil and gas exposure in the short term. See our latest analysis for BKV. That macro volatility sits...
NasdaqGS:OPCH
NasdaqGS:OPCHHealthcare

Expanded Buyback And Credit Facility Might Change The Case For Investing In Option Care Health (OPCH)

On March 30, 2026, Option Care Health expanded its revolving credit facility by US$450 million to US$850 million and increased its share repurchase authorization to US$1 billion, while reaffirming its 2026 guidance. The move strengthens liquidity and signals management’s confidence in cash generation, giving the company more flexibility to fund growth and return capital to shareholders. We’ll now examine how the expanded US$1 billion buyback authorization reshapes Option Care Health’s...